• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Positive ALKIVIA Myositis Data for VYVGART Hytrulo Altering The Investment Case For Zai Lab (ZLAB)?

    Simply Wall St·08/30/2026 23:27:31
    Listen to the news
    • Zai Lab and argenx previously reported positive topline Phase 3 ALKIVIA results for VYVGART Hytrulo in adults with autoimmune myositis, showing a statistically significant and clinically meaningful improvement in Total Improvement Score over 52 weeks versus placebo with a safety profile consistent with earlier studies.
    • This success in a disease area with no approved targeted therapies highlights the potential for FcRn inhibition to reshape treatment options across difficult-to-treat autoimmune muscle disorders.
    • We’ll now examine how these ALKIVIA results in autoimmune myositis could influence Zai Lab’s investment narrative around pipeline depth and future indications.

    Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    Zai Lab Investment Narrative Recap

    To own Zai Lab, you need to believe its partnered pipeline in oncology and immunology can translate into meaningful China and global revenues despite ongoing losses and competitive pressure. The ALKIVIA success in autoimmune myositis reinforces the breadth of the VYVGART franchise, but does not yet change the near term focus on execution of upcoming launches and label expansions, or the key risk around high external royalty and milestone burdens that weigh on the path toward profitability.

    Among recent announcements, the US$106.31 million Q2 2026 revenue and US$50.83 million net loss are especially relevant here, because they highlight how dependent Zai Lab still is on turning late stage assets like VYVGART Hytrulo into scaled commercial contributors. The stronger the evidence base across multiple autoimmune indications, the more credible the medium term revenue growth story becomes, but this sits alongside continued pressure to control costs and improve operating leverage.

    Yet even as ALKIVIA expands the promise around VYVGART, Zai Lab’s reliance on licensed assets and ongoing royalty obligations is a factor investors should be aware of...

    Read the full narrative on Zai Lab (it's free!)

    Zai Lab's narrative projects $832.0 million revenue and $157.9 million earnings by 2029. This requires 22.4% yearly revenue growth and an earnings increase of about $336 million from -$178.1 million today.

    Uncover how Zai Lab's forecasts yield a $33.30 fair value, a 28% upside to its current price.

    Exploring Other Perspectives

    ZLAB 1-Year Stock Price Chart
    ZLAB 1-Year Stock Price Chart

    Some of the most optimistic analysts were already penciling in roughly US$971.2 million of revenue and positive earnings potential by 2029, yet ALKIVIA’s success sits against their warning that heavy dependence on external licenses and royalties could still pressure margins, reminding you that views on Zai Lab’s upside and risk can differ widely and may need updating after this data.

    Explore 4 other fair value estimates on Zai Lab - why the stock might be worth 7% less than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.